PanoramicaGraficoNotizieSchermataTrader

BNP Paribas Knock-Out PFE/  DE000PN3CUL0  /

Frankfurt Zert./BNP
12/11/2024  21:50:23 Var.0.000 Denaro21:58:10 Lettera21:58:10 Sottostante Prezzo di esercizio Expiration date Tipo di opzione
0.600EUR 0.00% -
Quantità in denaro: -		 -
Quantità in lettera: -		 Pfizer Inc 20.0001 USD 31/12/2078 Call
TeleTrader 29/10 Pfizer's Q3 revenue jumps 31% to $17.7 billion
TeleTrader 07/10 Starboard Value allegedly takes $1B stake in Pfizer
TeleTrader 14/09 Pfizer reports positive data from experimental drug study
GlobeNewswire 03/09 Valneva and Pfizer Report Further Positive Phase 2 Booster Results for Lyme Disease Vaccine Candidat...
TeleTrader 27/08 Pfizer launches digital platform to 'simplify' healthcare access
TeleTrader 22/08 FDA okays Moderna, Pfizer updated vaccines
GlobeNewswire 22/08 Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vacc...
GlobeNewswire 16/08 Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and C...
TeleTrader 30/07 Pfizer's Q2 revenue rises by 2% to $13.3B
GlobeNewswire 17/07 Phase 3 VALOR Lyme Disease Trial: Valneva and Pfizer Announce Primary Vaccination Series Completion ...
TeleTrader 11/07 Pfizer advances once-daily version of weight loss pill
TeleTrader 09/07 Pfizer's chief scientific officer to leave after 15 years
GlobeNewswire 27/06 Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron JN.1-adapted COVID-19 Vaccine in the E...
GlobeNewswire 05/06 Relay Therapeutics Announces Clinical Trial Collaboration with Pfizer to Evaluate Atirmociclib in Co...
GlobeNewswire 03/06 Valneva Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious Diseases
GlobeNewswire 16/05 Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combinatio...
GlobeNewswire 09/05 Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medic...
TeleTrader 01/05 Pfizer's Q1 revenue drops 20% to $14.9 billion
GlobeNewswire 30/04 TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervica...
GlobeNewswire 22/03 Gastroenterologists Slow to Adopt Eli Lilly’s Omvoh, Pfizer’s Velsipity, and Takeda’s subcutaneous ...
GlobeNewswire 20/03 Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook
GlobeNewswire 07/03 BNTX DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel B...
GlobeNewswire 07/03 SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioNTe...
GlobeNewswire 05/03 LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd...
GlobeNewswire 28/02 SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in BioNTe...